Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 2 (2005), Issue 10 (October)

1. Medical treatment of juvenile idiopathic arthritis.
   JAMA, 294(13): 1671-84. [Abstract] [Full-text]
2. A comparison of fixed-bearing and mobile-bearing total knee arthroplasty at a minimum follow-up of 4.5 years.
   J Bone Joint Surg Am, 87(10): 2290-6. [Abstract] [Full-text]
3. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored.
   Arthritis Rheum, 53(5): 697-702. [Abstract] [Full-text]
4. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.
   Arthritis Rheum, 53(5): 703-9. [Abstract] [Full-text]
5. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis.
   Arthritis Rheum, 53(5): 710-7. [Abstract] [Full-text]
6. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany.
   Arthritis Rheum, 53(5): 740-7. [Abstract] [Full-text]
7. Visualization and in situ analysis of leukocyte trafficking into the ankle joint in a systemic murine model of rheumatoid arthritis.
   Arthritis Rheum, 52(10): 3269-78. [Abstract] [Full-text]
8. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
   Arthritis Rheum, 52(10): 3030-8. [Abstract] [Full-text]
9. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.
   Arthritis Rheum, 52(10): 3020-9. [Abstract] [Full-text]
10. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Arthritis Rheum, 52(10): 3058-62. [Abstract] [Full-text]
11. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors.
    Arthritis Rheum, 52(10): 3045-53. [Abstract] [Full-text]
12. Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population.
    Arthritis Rheum, 52(10): 3015-9. [Abstract] [Full-text]
13. Similar cell surface expression of beta2-microglobulin-free heavy chains by HLA-B27 subtypes differentially associated with ankylosing spondylitis.
    Arthritis Rheum, 52(10): 3290-9. [Abstract] [Full-text]
14. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis.
    Arthritis Rheum, 52(10): 3257-68. [Abstract] [Full-text]
15. Association between PADI4 and rheumatoid arthritis: a replication study.
    Arthritis Rheum, 52(10): 3054-7. [Abstract] [Full-text]
16. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?
    Arthritis Rheum, 52(10): 3039-44. [Abstract] [Full-text]
17. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis.
    Arthritis Rheum, 52(10): 3004-14. [Abstract] [Full-text]
18. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis.
    Arthritis Rheum, 52(10): 2996-3003. [Abstract] [Full-text]
19. Quantitative immunodetection of key elements of polyphosphoinositide signal transduction in osteoblasts from arthritic patients shows a direct correlation with cell proliferation.
    Histochem Cell Biol, 124(2): 131-7. [Abstract] [Full-text]
20. Willingness of patients with ankylosing spondylitis to pay for inpatient treatment is influenced by the treatment environment and expectations of improvement.
    Ann Rheum Dis, 64(11): 1650-2. [Abstract] [Full-text]
21. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis.
    Ann Rheum Dis, 64(11): 1647-9. [Abstract] [Full-text]
22. Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.
    Ann Rheum Dis, 64(11): 1532-8. [Abstract] [Full-text]
23. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.
    Ann Rheum Dis, 64(11): 1582-7. [Abstract] [Full-text]
24. ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis.
    Ann Rheum Dis, 64(11): 1576-81. [Abstract] [Full-text]
25. Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study.
    Ann Rheum Dis, 64(11): 1588-94. [Abstract] [Full-text]
26. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.
    Ann Rheum Dis, 64(11): 1595-601. [Abstract] [Full-text]
27. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Ann Rheum Dis, 64(11): 1557-62. [Abstract] [Full-text]
28. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Ann Rheum Dis, 64(11): 1568-75. [Abstract] [Full-text]
29. Occurrence and risk factors for falls in rheumatoid arthritis.
    Ann Rheum Dis, 64(11): 1602-4. [Abstract] [Full-text]
30. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
    Ann Rheum Dis, 64(11): 1563-7. [Abstract] [Full-text]
31. How does B cell depletion therapy work, and how can it be improved?
    Ann Rheum Dis, 64: iv77-80. [Abstract] [Full-text]
32. Health economics: implications for novel antirheumatic therapies.
    Ann Rheum Dis, 64: iv65-9. [Abstract] [Full-text]
33. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Ann Rheum Dis, 64: iv61-4. [Abstract] [Full-text]
34. Presentation and analysis of radiographic data in clinical trials and observational studies.
    Ann Rheum Dis, 64: iv48-51. [Abstract] [Full-text]
35. Biological drug use: US perspectives on indications and monitoring.
    Ann Rheum Dis, 64: iv18-23. [Abstract] [Full-text]
36. Secondary renal amyloidosis due to long-standing tubulointerstitial nephritis in a patient with Sjögren syndrome.
    Am J Kidney Dis, 46(5): e75-80. [Abstract] [Full-text]
37. Animal models of arthritis caused by systemic alteration of the immune system.
    Curr Opin Immunol, 17(6): 589-94. [Abstract] [Full-text]
38. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy.
    Brain, 128: 2518-34. [Abstract] [Full-text]

© 2004-2012 Rheumatoid Arthritis Research Today. All Rights Reserved.